HPV 백신 시대에 HPV DNA Chip 검사의 임상효용성- 1,211예 분석, 단일기관 보고 -
Clinical Efficacy of HPV DNA Chip Test in the Era of HPV Vaccination- 1,211 Cases, A Single Institution Study -
2
조회
0
다운로드
6
인용
0
참고문헌
초록
Abstract
Background : Human papillomavirus (HPV) prophylactic vaccines, bivalent types for HPV-16/18 with 70% prophylactic expectation, have been developed based on the genotypes found prevalent in the western countries, but little is known for those in Korea. Using a DNA chip test, we evaluated the clinical efficacy of HPV genotype based on cervical abnormalities. Methods : As the initial diagnostic tests, HPV DNA chip tests and Papanicolaou smear (PAP) were used for 1,211 subjects. Cervical colposcopy directed biopsies were performed for 626 among the 1,211 subjects within one month. Results : The most frequently found genotypes in all HPV-positive specimens (n=445) were HPV- 16 (22.0%), 58 (13.9%), 52 (11.0%), 51 (9.0%), 56 (8.5%), and 18 (7.2%). HPV prevalence was significantly higher in specimens where PAP and biopsy results were closer to malignancy. The HPV genotype distribution of the histologically confirmed cervical high-grade squamous intraepithelial lesions (HSIL) or carcinoma cases showed HPV-16, 58, 52, 18, and 33, in descending order. The HPV DNA chip sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for the detection of cervical HSIL or carcinoma were 76.9%, 70.1%, 72.1%, and 75.8%, respectively, Of these, the sensitivity and NPV were higher than those of PAP. PPV and NPV of HPV-16 were 90.5% and 60.7%, respectively, being the highest among the genotypes. Conclusions : We confirmed that HPV-16 genotype was also very important for the diagnosis of HSIL and cervical carcinoma in Korea. However, contrary to the findings in the western countries, the prevalence of HPV-58 was higher than that of HPV-18. Moreover, as the other HPV genotype reports were rare in Korea, further studies are required with the HPV DNA chip test before the nationwide adoption of the vaccines. (Korean J Lab Med 2008;28:70-8)
참고문헌 (22)
- Bosch FX, "Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group", J Natl Cancer Inst, 87, pp.796~802 (1995)
- Clifford GM, "Human papillomavirus types in invasive cervical cancer worldwide: a metaanalysis", Br J Cancer, 88, pp.63~73 (2003)
- Hwang HS, "Distribution and prevalence of human papillomavirus genotypes in routine pap smear of 2,470 Korean women determined by DNA chip", Cancer Epidemiol Biomarkers Prev, 13, pp.2153~2156 (2004)
- An HJ, "Correlation of cervical carcinoma and precancerous lesions with human papillomavirus (HPV) genotypes detected with the HPV DNA chip microarray method", Cancer, 97, pp.1672~1680 (2003)
- Cho NH, "Genotyping of 22 human papillomavirus types by DNA chip in Korean women: comparison with cytologic diagnosis", Am J Obstet Gynecol, 188, pp.56~62 (2003)
- 김성림, "자궁경부 및 질 분비물에서 자가채취 패드를 이용한 인유두종바이러스 검출에 관한 연구", 대한병리학회지, 38(4), pp.258~264 (2004), 대한병리학회
- Solomon D, "The 2001 Bethesda System: terminology for reporting results of cervical cytology", JAMA, 287, pp.2114~2119 (2002)
- "Gynecologic Oncology Committee of the Korean Society of Obstetrics and Gynecology. Annual report of gynecologic cancer registry program in Korean for 2002 (Jan. 1st, 2002-Dec. 31st, 2002). Korean J Obstet Gynecol 2004;47:1029-70. (대한산부인과학회 부인종양위 원회. 한국 부인암 등록사업 조사보고서(2002.1.1-2002.12.31). 대한 산부인과학회지 2004;47:1029-70.)", ~ (2002)
- Nanda K, "Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review", Ann Intern Med, 132, pp.810~819 (2000)
- Sasieni PD, "Estimating the efficacy of screening by auditing smear histories of women with and without cervical cancer. The National Co-ordinating Network for Cervical Screening Working Group", Br J Cancer, 73, pp.1001~1005 (1996)
- Woon-Won Jung, "Strategies Against Human Papillomavirus Infection and Cervical Cancer", The Journal of Microbiology, 42(4), pp.255~266 (2004), 한국미생물학회
- Franco EL, "Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control", Vaccine, 23, pp.2388~2394 (2005)
- Adam E, "Papillomavirus detection: demographic and behavioral characteristics influencing the identification of cervical disease", Am J Obstet Gynecol, 182, pp.257~264 (2001)
- Burk RD, "Declining prevalence of cervicovaginal human papillomavirus infection with age is independent of other risk factors", Sex Transm Dis, 23, pp.333~341 (1996)
- Kulasingam SL, "Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral", JAMA, 288, pp.1749~1757 (2002)
- de Cremoux P, "Efficiency of the hybrid capture 2 HPV DNA test in cervical cancer screening. A study by the French Society of Clinical Cytology", Am J Clin Pathol, 120, pp.492~499 (2003)
- Franco EL, "Cervical cancer: epidemiology, prevention, and the role of human papillomavirus infection", CMAJ, 164, pp.1017~1025 (2001)
- Solomon D, "ALTS study group. Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial", J Natl Cancer Inst, 93, pp.293~299 (2001)
- Kim JJ, "Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy", J Natl Cancer Inst, 97, pp.888~895 (2005)
- Goldie SJ, "Cost-effeciveness of human papillomavirus DNA testing for cervical cancer screening in women aged 30 years or more", Obstet Gynecol, 103, pp.619~631 (2004)
- Yitalo N, "Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study", Lancet, 355, pp.2179~2180 (2000)
- Elfgren K, "A population- based five-year follow-up study of cervical human papillomavirus infection", Am J Obstet Gynecol, 183, pp.561~567 (2000)